CONTENT MARKETING SOLUTIONS
Pharmaceutical Executive is proud to offer a multi-platform suite of print, digital, and content marketing solutions designed to extend your reach and enhance the value and credibility of your content.
Print Publication & Supplements
Print Publication & Supplements
Targeted Supplements
Content Marketing Solutions
Dediated Dialogue
Solution Center
Mobile Apps
Podcasts
Digital Edition & E-Books
Global Digital Edition
Focused e-Books
Custom Audience Segmentation Tool (CAST)
Content Targeting to the Right Audience
Webinars
Sponsored & Educational Cutting-Edge
Content from Industry Leaders
Enhanced Webcast Program
Website
www.pharmexec.com
E-Newsletters
PharmExec Direct e-Newsletter
PharmExec Marketing e-Newsletter
PEGD e-newsletter
|
|
FEATURES
* Content subject to change
Industry Audit
Pharm Exec’s 14th Annual Industry Audit takes an in-depth look at the business of pharma, ranking the top 25 companies on more than a dozen key metrics to identify the industry’s top performer in actually delivering shareholder value. A hint: it’s the smaller, more focused players that stand out—we call it the “stealth effect."
Piercing the Veil
This feature examines the trend toward consolidation of the payer base, as represented by the growing market reach of PBMs, along with the emerging universe of new provider networks, such as accountable care organizations, medical homes, and integrated delivery networks. The implications for pharma will be explored, including how drugmakers in the US can effectively compete for market share in an environment where a select few managed care organizations now control access to almost 80% of treatment.
R&D Efficiency: The ACRES Approach
It’s widely acknowledged that a significant portion of drug research spending is wasted on inefficiencies. For several years, there has been a plea to rein in these inefficiencies by groups like the Alliance for Clinical Research Excellence and Safety (ACRES). Pharm Exec speaks with Greg Koski, president and CEO of ACRES, who believes that a systems approach will be necessary to bring the plethora of stakeholders involved in drug research to a common view.
|